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PIH18  
COSTS OF GLOBAL ENDOMETRIAL ABLATION (GEA) FOR TREATMENT OF 
HEAVY MENSTRUAL BLEEDING (MENORRHAGIA): ASSIMILATION AND 
COMPARISON OF RESULTS FROM PUBLISHED COST-EFFECTIVENESS  
MODELING STUDIES  
Miller JD 
Truven Health Analytics, Cambridge, MA, USA  
OBJECTIVES: Most cost-effectiveness modeling studies of global endometrial 
ablation (GEA) for treatment of heavy menstrual bleeding (menorrhagia) are from 
a UK perspective. Costs and cost-effectiveness information about GEA from a US 
perspective are lacking. Study objectives were: 1) identify/review all cost-
effectiveness modeling studies of GEA; 2) assimilate GEA costs across these 
studies at current levels (2012 US dollars) to proxy a US market perspective; and 
3) perform statistical summarizations of the data. METHODS: All published 
literature and health technology assessments of menorrhagia treatment cost-
effectiveness published 2004-2012 were reviewed; studies with GEA as a 
comparator were selected for inclusion. GEA cost data were abstracted and 
converted to US dollars using purchasing power parity indices (PPPI) and 
adjusted to 2012 levels using the US consumer price index (CPI). Statistical 
summarizations (minimum, maximum, mean, median) were performed for 
studies in their respective 1-, 2-, 5-, and 10-year analysis scenarios. RESULTS: 
From a total of eight cost-effectiveness modeling studies, 14 GEA cost data values 
were abstracted. All values pertained to either microwave endometrial ablation 
(MEA) or thermal balloon endometrial ablation (TBEA), or a composite weighted 
average of the two techniques. No studies reported costs associated with 
cryoablation, bipolar radiofrequency ablation, or hydrothermal ablation (HTA). 
Adjusted GEA costs from two 1-year analyses ranged from $1,011 to $1,329 
(mean/median $1,170). Costs from a single 2-year analysis were $2140. Costs 
from four 5-year analyses ranged from $2700 to $3748 (mean $3359, median 
$3493). Costs from seven 10-year analyses ranged from $2495 to $4549 (mean 
$3264, median $3119). CONCLUSIONS: There was a large degree of heterogeneity 
in scope and comprehensiveness of cost accounting in the GEA cost analyses 
summarized here. Although only proxy estimates of GEA costs in the US, results 
of this study serve as useful benchmarks for cost evaluations of GEA in the 
dramatically changing menorrhagia-treatment market.  
 
PIH19  
A CASE-CONTROLLED, RETROSPECTIVE ANALYSES OF PRETERM LABOR AND 
PRETERM BIRTH IN PREMIER'S PERSPECTIVE HOSPITAL DATABASE (2003-2010)  
Black L1, Carroll C2 
1GlaxoSmithKline, Research Triangle Park, NC, USA, 2GlaxoSmithKline, RTP, NC, USA  
OBJECTIVES: To profile a cohort of women and infants who received a diagnosis 
of preterm labor (PTL)/preterm birth (PTB), and to compare the health care 
burden of these cohorts to term deliveries/infants. METHODS: Retrospective 
analysis of Premier Perspective Hospital Database. Sample populations of 
women who delivered and infants who were born (2003-2010), were identified 
and a case controlled analysis was conducted comparing PTL-deliveries/PTB-
infants with term deliveries/infants. Secondary outcomes included summaries of 
resource utilization and costs. Maternal cases and controls and infant cases and 
controls were matched 1 to 1, based on year of delivery/birth, mother’s delivery 
age (mothers only), race, provider area, rural/urban, and payor type. RESULTS: A 
total of 432,808 women had a diagnosis code of PTL with delivery, the fewest 
(9.4%) in 2003 and the most (15.5%) in 2009. Tocolytic drug use was recorded in 
37% of cases. Cases with delivery had a mean length of stay (LOS) of 3.06 days 
(controls = 2.25 days) and mean per patient costs of $8032 (controls = $5311). 
There were 314,577 case infants with either a gestational age (GA) ICD9 code or a 
birth weight ICD9 code. Total mean cost per case with in-hospital deaths 
included was $70,074 (controls = $4,505). More deaths occurred in the case cohort 
versus the control cohort (6941 vs. 121, respectively). The case mean hospital LOS 
was 14.27 days (controls = 2.39 days). The extremely premature (<25-26 wks) 
made up approximately 4% of PTBs and 22% of total hospital costs versus late 
preterm (33-36 wks) made up approximately 69% of PTBs and 30% of total 
hospital costs. CONCLUSIONS: The most extreme premature infants accounted 
for 22% of the total preterm hospital costs. Being able to prolong the pregnancy 
across the entire GA range, but particularly in the very preterm, has the potential 
for substantial cost savings.  
 
PIH20  
HEALTH-ECONOMICS ANALYSIS OF DISEASES RELATED TO THE 
DISTURBANCES OF ADAPTATION: A COST OF ILLNESS STUDY  
Boncz I, Kovacs GL, Ertl T, Ágoston I, Molics B, Bódis J 
University of Pécs, Pécs, Hungary  
OBJECTIVES: The aim of our study is to perform the health-economics analysis 
of diseases related to disturbances of adaptation by a cost of illness study in 
Hungary. METHODS: Data were derived from the financial dataset of the 
National Health Insurance Fund Administration (OEP) covering the year 2009. 
Four disease were included into the analysis: polycystic ovary syndrome (E2820), 
retinopathy of prematurity (H3510), a hyperstimulation of ovaries (N9810) and 
respiratory distress syndrome of newborn (P2200). RESULTS: The annual health 
insurance cost of diseases were the following: polycystic ovary syndrome: 78.9 
million Hungarian Forint (HUF) or EUR€281,160, retinopathy of prematurity: HUF 
41.3 million (EUR€147,090), hyperstimulation of ovaries: HUF 8.7 million 
(EUR€30,839) and respiratory distress syndrome of newborn: HUF 1.562 million 
(EUR€5,567,336). We found by far the highest annual per capita health insurance 
expenditure in respiratory distress syndrome of newborn (HUF 1.43 million or 
EUR€5098/patient/year). Hyperstimulation of ovaries (HUF 58,073 or 
EUR€207/patient/year), retinopathy of prematurity (HUF 19,513 or EUR€70/ 
patient/year) and polycystic ovary syndrome (HUF 7679 or EUR€27/patient/year) 
showed significantly lower annual per capita health insurance expenditure. 
CONCLUSIONS: The annual health insurance expenditures of diseases related to 
the disturbances of adaptation are high (HUF 1689 million or EUR€6.02 million) 
and among that diseases respiratory distress syndrome of newborn has the 
highest burden of disease.  
 
PIH21  
MEDICAL, DRUG, AND WORK-LOSS COSTS OF VENOUS LEG ULCERS  
Rice JB1, Desai U1, Cummings AK1, Birnbaum HG1, Skornicki M2, Parsons N2 
1Analysis Group, Inc., Boston, MA, USA, 2Organogenesis Inc., Canton, MA, USA  
OBJECTIVES: Estimate annual per-patient medical, drug, and work-loss costs of 
venous leg ulcers (VLU) using de-identified administrative claims data. 
METHODS: Beneficiaries with (VLU) and without VLU (controls) were identified 
using two databases: ages 65+ from a 5% random sample of Medicare 
beneficiaries (Standard Analytical Files, 2007-2010; VLU N=60,840, controls N= 
699,506) and ages 18-64 from a privately-insured population (OptumInsight, 
2007-2011; VLU N=26,096, controls N= 1,300,455). Patients were required to be 
continuously eligible during the 12 months before (baseline) and 12 months after 
(study period) the index date (i.e., the date of the most recent VLU diagnosis 
following 12 months without VLU diagnoses (VLU group); or the date of a random 
medical claim (controls)). VLU patients were matched to controls using 
propensity scores to account for baseline differences in demographics, 
comorbidities, resource utilization, and costs. Medical costs incurred during the 
study period were calculated for both Medicare and privately-insured patients. 
Because drug and work-loss (absenteeism or disability) data were unavailable for 
Medicare patients, these costs were estimated for the privately-insured sample 
only. Differences in study period costs were compared using Wilcoxon signed-
rank tests. RESULTS: Data for 22,900 matched pairs of privately-insured and 
58,616 matched pairs of Medicare patients were analyzed. VLU patients incurred 
incremental medical costs of $6,080 in Medicare ($18,246 vs. $12,165), with 
privately-insured VLU patients having excess medical costs of $7,012 ($13,552 vs. 
$6,540). Among the privately-insured, 89% of the cost differential was 
attributable to excess inpatient and outpatient/physician office costs. For 
Medicare, the excess costs were approximately equally distributed among all 
places of services. Among the privately-insured, the VLU patients and controls 
incurred similar drug costs, however, VLU patients had $454 more in work-loss 
costs (absenteeism: +$367, disability: +$87). (Comparisons significant at 
p<0.0001). CONCLUSIONS: With VLU incidence estimates of 2.5 million, these 
findings suggest an annual payer burden up to $18 billion.  
 
PIH22  
COMPARATIVE DIRECT AND INDIRECT COSTS OF MENORRHAGIA TREATMENT 
WITH GLOBAL ENDOMETRIAL ABLATION OR HYSTERECTOMY  
Bonafede MM, Miller J, Meyer NM, Lenhart GM 
Truven Health Analytics, Cambridge, MA, USA  
OBJECTIVES: To describe the treatment patterns, health care utilization, medical, 
and productivity costs among commercially insured women initiating 
menorrhagia treatment with global endometrial ablation (GEA) or hysterectomy. 
METHODS: Women aged 30-55 years with diagnosed menorrhagia who initiated 
menorrhagia treatment with GEA or hysterectomy (index event) during 2006-
2010 were identified in the Truven Health MarketScan® Commercial Claims and 
Encounters Database. One-year of continuous enrollment pre- and post-index 
event was required to evaluate baseline characteristics and outcome measures. 
Health care utilization and costs (2011 USD) were assessed in the year following 
treatment initiation. Workplace absenteeism and short-term disability (STD) 
costs were reported for a subset of patients. RESULTS: Two-thirds (66.3%) of the 
61,602 study patients initiated menorrhagia treatment with GEA compared to 
hysterectomy (33.7%). Average age was similar between treatments (43.2 years), 
as was the baseline Deyo-Charlson Comorbidity score (0.17), and use of 
prescription non-steroidal anti-inflammatory drugs (29%). The majority (96%) of 
GEA procedures occurred in an outpatient setting compared to 18% of 
hysterectomy procedures. Treatment-related complications were more common 
for hysterectomy (36%) than for GEA (15%, p<0.001). Treatment initiation and 30-
day followup costs were higher for hysterectomy ($12,147) than for GEA ($5,837, 
p<0.001), as were gynecologic-related costs for remainder of the year ($284 vs. 
$147, p<0.001). Absenteeism costs in the year following treatment initiation were 
higher for hysterectomy ($7543) than for GEA ($5621, p<0.001). Hysterectomy 
patients were four times more likely to have a STD claim than GEA patients (84% 
vs. 21%, p<0.001) with similar costs per-claim ($6802 vs. $6472, p=0.29), which 
resulted in higher per-patient STD costs across all patients ($5744 vs. $1361, 
p<0.001). CONCLUSIONS: Hysterectomy cost was nearly two times higher than 
GEA for menorrhagia treatment. Lost productivity represented a significant 
portion of this cost difference as hysterectomy patients were substantially more 
likely to have a STD claim and had higher costs per claim.  
 
PIH23  
COST-EFFECTIVENESS OF 13-VALENT VERSUS 23-VALENT PNEUMOCOCCAL 
POLYSACCHARIDE VACCINE AND NO VACCINATION IN THE CZECH NATIONAL 
VACCINATION PROGRAM  
Zigmond J1, Tichopad A1, Kolek V2, Roberts CS3, Hajek P4 
1CEEOR s.r.o., Prague, Czech Republic, 2Olomouc University Hospital, Olomouc, Czech Republic, 
3Pfizer, New York, NY, USA, 4Pfizer s r.o., Prague, Czech Republic  
OBJECTIVES: Czech guidelines recommend 23-valent pneumococcal 
polysaccharide vaccination (PPSV23) for people living in homes for the elderly, 
long-term hospitals, homes for the disabled and special-regime homes (the  
last two were excluded for lack of valid data, assuming that wouldn’t influence 
results since they make only a negligible part of vaccinated people). A 13-valent 
pneumococcal conjugate vaccine (PCV13) has had significant public-health 
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impacts in children and is currently being evaluated for use in adults in  
the Czech Republic (CR). The objective of this study was to assess the  
cost-effectiveness of pneumococcal vaccination strategies in the elderly 
population. METHODS: A first-order Markov decision-analytic model was 
developed to compare cost-effectiveness of vaccination with PCV13, PPSV23  
and no vaccination in the Czech Republic. PPSV23 effectiveness was derived 
from literature and PCV13 was extrapolated from impact in children adjusting 
for immunosenescence in older persons. Pneumonia, bacteremia and meningitis 
hospitalization and cost data were acquired from health authorities and  
DRG system in CR; outpatient data were based on retrospective patient survey. 
The model used a lifetime time horizon and 3% discount rate. RESULTS:  
Used according to Czech guidelines, PCV13 vaccination is associated with 0.0002 
life-years gained for an additional EUR 1.002 on average (EUR 3,812,478 in total) 
compared to no vaccination and 0.0004 life-years gained for additional EUR 0.97 
on average (EUR 3,704,061 in total) compared to PPSV23. This leads to an ICER  
of EUR/LYG 4,950 and 2,265 under current reimbursement. If all moderate  
and high risk people were vaccinated, the ICER would increase to EUR/LYG 5,582 
and 6,691, respectively, under current reimbursement and to ICER of EUR/LYG 
8,676 and 7,057 under full reimbursement. CONCLUSIONS: Confronting  
the national GDP per capita with the WHO recommendation on health care 
spending per QALY gained, PCV13 national immunization program in the Czech 
Republic can be considered cost-effective even under a full reimbursement 
policy.  
 
PIH24  
COST IMPACT OF A COMPREHENSIVE STI SCREENING STRATEGY,  
INCLUDING CHLAMYDIA, GONORRHEA AND TRICHOMONIASIS: A US PAYER 
PERSPECTIVE  
Hertz D1, Mehringer M2, Sulham K1, Garfield S1 
1GfK Bridgehead, Wayland, MA, USA, 2Hologic Gen-Probe, San Diego, CA, USA  
OBJECTIVES: Chlamydia (CT), gonorrhea (GC) and trichomoniasis (TV) screening 
can be conducted simultaneously on a single sample using nucleic acid 
amplification testing (NAAT). NAAT has made screening faster and more 
sensitive. Targeted CT/GC screening has long been supported by clinical 
guidelines (USPSTF, CDC, and ACOG) and research has shown screening to be 
cost-effective from a health-system perspective. Despite this, testing rates are 
low (estimated at 38% by the CDC). Here, we explore the clinical and economic 
impact of increasing adherence to screening guidelines for CT/GC and the 
introduction of TV screening from a US payer perspective. METHODS: A 
decision-tree cost-impact model was developed to compare current screening 
rates for CT/GC with a hypothetical increase in CT/GC screening uptake and the 
addition of TV screening in women 15-24yrs. with high-risk sexual behavior. 
Model components included testing, treatment, confirmation of eradication, and 
adverse events for women 15-24. Inputs were based on published literature. The 
model examines member cost (excluding partner transmission) and clinical 
impact of an increase in screening uptake over 1 year. RESULTS: For a 
hypothetical member population of 5.0M, with a baseline CT/GC/TV prevalence 
of 4.7/2.2/8.4%, increasing CT/GC screening uptake by 10% and adding 
simultaneous TV screening has an incremental cost per additional STI detected 
over a 5-year, 7-year, and lifetime time horizon of $376.18, $272.26, and $30.01, 
respectively. The incremental cost per adverse event avoided was $2,239.00, 
$1,541.86, $182.22, respectively. Lifetime adverse events avoided (discounted) 
include: 215 cases of PID, 93 PID-related sequelae, 14 adverse pregnancy 
outcomes and 0.8 HIV cases. CONCLUSIONS: Given its high prevalence, high rate 
of asymptomatic cases and the severity of the health consequences, TV should 
be considered as part of a comprehensive STI screening strategy. Increasing 
targeted screening for CT/GC/TV could be a cost-effective way of improving 
women’s health and a health plan’s quality of care.  
 
PIH25  
COST-EFFECTIVENESS OF VAGINAL PROGESTERONE GEL IN REDUCING 
PRETERM BIRTH: A DECISION ANALYTIC MODEL BASED ON THE PREGNANT 
RANDOMIZED CLINICAL TRIAL  
Pizzi LT1, Seligman N2, Baxter J3, Jutkowitz E4, Prioli KM1, Mearns E5, Berghella V3 
1Thomas Jefferson University, Philadelphia, PA, USA, 2University of Rochester Medical Center, 
School of Medicine and Dentistry, Rochester, NY, USA, 3Jefferson Medical College, Philadelphia, 
PA, USA, 4University of Minnesota, Minneapolis, MN, USA, 5Jefferson School of Pharmacy, 
Philadelphia, PA, USA  
OBJECTIVES: Preterm birth (PTB) is a costly public health problem that causes 
significant neonatal morbidity and mortality. To determine cost-effectiveness of 
vaginal progesterone (VP) gel in the prevention of preterm birth (PTB), we 
developed a decision analytic model using data from the PREGNANT trial. 
METHODS: PREGNANT was a multi-center, international RCT in which 459 
women with singleton gestations and short cervix (10-20mm by transvaginal 
ultrasound) were randomized to daily VP 8% gel (n=235) or placebo (n=224). 
Patient-level trial data along with cost data from the literature were used to 
develop the model (TreeAge Pro 2011). Births were categorized by gestational age 
at delivery: PTB at <28 weeks, PTB at 28-31 weeks, PTB at 32-36 weeks, or full 
term (≥37 weeks). Costs ($US 2011) included cervical length screening, VP gel 
(treatment group only), antenatal hospitalizations, cerclage, and delivery 
hospitalization (maternal + neonatal costs). The main outcome measure was 
incremental cost-effectiveness, calculated as the difference in total costs 
between the VP gel group and the placebo group, divided by the difference in the 
number of PTB averted between the VP gel group and the placebo group. A 
probabilistic sensitivity analysis (PSA) with 10,000 simulations was used to 
determine cost-effectiveness when both cost and outcome data were varied 
within defined limits. RESULTS: Model base case incremental savings for VP 
were $12,354 and an incremental benefit of VP was 0.042 PTB averted 
(ICER=$21,063/PTB averted). The PSA indicated that VP gel is expected to be less 
costly and more effective than placebo in 79.2% of simulated cases, however, less 
costly but ineffective in 16.8% of simulated cases. CONCLUSIONS: VP gel is cost-
effective in the prevention of PTB in women with short cervix as compared to 
placebo in most cases. Results inform ongoing clinical controversies regarding 
the value of VP as a preventive modality for PTB.  
 
PIH26  
HEALTH ECONOMIC EVIDENCE IN SUPPORT OF A LONG-ACTING REVERSIBLE 
CONTRACEPTIVE METHOD: LNG-IUS-12, A LOW-DOSE CONTRACEPTIVE 
LEVONORGESTREL INTRAUTERINE SYSTEM  
Trussell J1, Hassan F2, Henry N2, Law AW3, Pocoski J3, Filonenko A4 
1Princeton University, Princeton, NJ, USA, 2IMS Health, London, UK, 3Bayer HealthCare 
Pharmaceuticals Inc, Wayne, NJ, USA, 4Bayer Pharma AG, Berlin, Germany  
OBJECTIVES: LNG-IUS-12 is a low-dose hormonal intrauterine contraceptive 
system for up to 3 years of use. This analysis aimed to evaluate the cost-
effectiveness of LNG-IUS-12 in comparison to short-acting reversible 
contraceptive (SARC) methods in a cohort of young women in the United States 
(US) from a third-party payer’s perspective. METHODS: A state-transition model 
was developed to assess cost-effectiveness of LNG-IUS-12 versus SARC methods 
over 3 years in 1000 women aged 20-29 years, the age group accounting for over 
half of all abortions in the US. SARC methods comprise of oral contraceptives, 
ring, patch and injections – methods commonly used by this cohort. The model 
consisted of three mutually exclusive health states: initial method, unplanned 
pregnancy (UP) and subsequent method. Subsequent method is represented by a 
mixed market-weighted contraceptive ‘basket’. Failure and discontinuation rates 
were based on published literature. Unit costs were taken from standard US 
databases. Cost and effectiveness metrics for SARC were weighted using market 
share data. The key model output was cost per UP avoided. One-way sensitivity 
analyses (OWSA) and probabilistic sensitivity analyses (PSA) were performed. 
RESULTS: LNG-IUS-12 dominated SARC, resulting in fewer UP (65.26 vs. 278.97) 
and lower total costs ($1,274,295USD vs. $1,822,836USD, a 43% saving) over 3 
years. The costs associated with subsequent method used by women who 
initiated LNG-IUS-12 were lower ($107,587USD vs. $230,024USD) due to lower 
failure and discontinuation rates of LNG-IUS-12. OWSA results were insensitive 
to variation in key input parameters. PSA results indicate a high probability of 
dominance as all iterations were less costly and more effective. CONCLUSIONS: 
From a third-party payer perspective, LNG-IUS-12 is a more cost-effective 
contraceptive option than SARC. Therefore, women switching from current SARC 
use to LNG-IUS-12 are likely to generate cost savings to third-party health care 
payers, driven principally by decreased UP-related expenditures and long-term 
savings in contraceptive costs.  
 
PIH27  
COST EFFECTIVENESS ANALYSIS OF MEDICAL MANAGEMENT OF INCOMPLETE 
MISCARRIAGES IN THE BAHAMAS  
Sakharkar P1, Sakharkar V2 
1Roosevelt University College of Pharmacy, Schaumburg, IL, USA, 2University of the West Indies, 
School of Clinical Medicine & Research, Nassau, Bahamas  
OBJECTIVES: About 30% of all pregnancies end in first trimester and half of them 
present as an incomplete miscarriage. It is a significant health issue raising 
economic burden on the publicly funded health care system in the Bahamas. 
Surgical evacuation is the most commonly used treatment which involves 
operating theater and inpatient costs in cases of complications like cervical 
trauma, uterine perforation, hemorrhage and infection. The objective of this 
study was to conduct a cost effectiveness analysis (CEA) of medical management 
(Misoprostol) versus surgical procedure in the management of incomplete 
miscarriages in the Bahamas, from a societal perspective. METHODS: Cost and 
probabilities of outcomes were derived from the hospital data and published 
literature. Cost of medical and surgical management included direct & indirect 
costs viz. physician cost, procedure cost, cost of ultrasounds, drug cost, cost of 
hospital stay, complications & adverse events; loss of wages and cost of travel. 
Primary outcomes were treatment success and failure. A one way sensitivity 
analyses were conducted by varying the cost and success by 25% & 15%, 
respectively. RESULTS: The CEA showed that, medical management (US$719 per 
patient) was the least costly alternative to surgical procedure (US$2,135 per 
patient). The incremental cost effectiveness ratio (ICER) of medical management 
was - $1,416 and proved to be the dominant option being less expensive and 
having comparable treatment success. Results were sensitive to variations in 
costs by 25% and success rate by 15% indicating domination of medical 
management suggesting being less expensive both to the patient as well as to 
the payer. CONCLUSIONS: From a societal perspective, medical management 
appears to be the least costly approach for the treatment of incomplete 
miscarriages in the Bahamas; and should be considered as the first line 
management. Further investigations are needed to obtain costs savings on long 
term horizon.  
 
PIH28  
COST-EFFECTIVENESS ANALYSIS OF USING LEVONORGESTREL-RELEASING 
INTRAUTERINE SYSTEM IN LONG-TERM CONTRACEPTION IN COLOMBIA  
Romero M1, Huerfano L1, Espinel F2 
1Fundacion Salutia, Bogota, Colombia, 2Clinica de la Mujer, Bogota, Colombia  
OBJECTIVES: To evaluate the cost-effectiveness of levonorgestrel-releasing 
intrauterine system (LNG-IUS) as a long-term contraceptive method compared 
with similar methods, from the state perspective METHODS: A Markov chain 
model is developed to evaluate pregnancies avoided as outcome of interest. The 
model was built in monthly cycles at a five-year time horizon for a hypothetical 
cohort of 1,000 women of childbearing age and includes probabilities of 
